First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Average Rating of “Buy” from Analysts

First Tracks Biotherapeutics (NASDAQ:TRAX) has earned an average recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $39.4286.

A number of equities analysts have commented on TRAX shares. Barclays started coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price objective for the company. Piper Sandler started coverage on shares of First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 price objective for the company. Leerink Partners started coverage on shares of First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $46.00 price objective for the company. Zacks Research upgraded shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. Finally, UBS Group started coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 price target for the company.

First Tracks Biotherapeutics Stock Up 0.9%

Shares of First Tracks Biotherapeutics stock opened at $15.96 on Friday. First Tracks Biotherapeutics has a one year low of $14.79 and a one year high of $26.80.